Document is current
Any future updates will be listed below
-
Authors
Kim, Ji Yun
Brown, Emily
Aquino, Jose
Mao, Cherry
Mrouj, Karim
Arrojwala, Manu
Kopetz, Scott
Hong, Yong Sang
Mizrahi, Jonathon
Rhee, Joon
Beagle, Brandon
DiRenzo, Daniel
Walters, Matthew
Kaplan, Angelo
Cho, Sean
Kabbarah, Omar
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04660812 at ClinicalTrials.govnct04660812 at ClinicalTrials.govDocuments that mention this clinical trial
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
https://doi.org/10.1136/jitc-2021-004089
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).
https://doi.org/10.1200/jco.2024.42.16_suppl.3508
52 The adenosine receptor antagonist etrumadenant reduces tumor adenosine-regulated NR4A gene expression and increases mCRC inflammation in patients from the ARC-9 trial
https://doi.org/10.1136/jitc-2024-sitc2024.0052
Documents that mention this clinical trial
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
https://doi.org/10.1136/jitc-2021-004089
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).
https://doi.org/10.1200/jco.2024.42.16_suppl.3508
52 The adenosine receptor antagonist etrumadenant reduces tumor adenosine-regulated NR4A gene expression and increases mCRC inflammation in patients from the ARC-9 trial
https://doi.org/10.1136/jitc-2024-sitc2024.0052
- License Information
